Journal Article
. 2013 Feb;133(4).
doi: 10.1002/ijc.28082.

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

C A Drukker 1 J M Bueno-de-Mesquita  V P Retèl  W H van Harten  H van Tinteren  J Wesseling  R M H Roumen  M Knauer  L J van 't Veer  G S Sonke  E J T Rutgers  M J van de Vijver  S C Linn  
Affiliations
  • PMID: 23371464
  •     19 References
  •     61 citations

Abstract

The 70-gene signature (MammaPrint™) has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant metastases. The microarRAy-prognoSTics-in-breast-cancER (RASTER) study was the first study designed to prospectively evaluate the performance of the 70-gene signature, which result was available for 427 patients (cT1-3N0M0). Adjuvant systemic treatment decisions were based on the Dutch CBO 2004 guidelines, the 70-gene signature and doctors' and patients' preferences. Five-year distant-recurrence-free-interval (DRFI) probabilities were compared between subgroups based on the 70-gene signature and Adjuvant! Online (AOL) (10-year survival probability <90% was defined as high-risk). Median follow-up was 61.6 months. Fifteen percent (33/219) of the 70-gene signature low-risk patients received adjuvant chemotherapy (ACT) versus 81% (169/208) of the 70-gene signature high-risk patients. The 5-year DRFI probabilities for 70-gene signature low-risk (n = 219) and high-risk (n = 208) patients were 97.0% and 91.7%. The 5-year DRFI probabilities for AOL low-risk (n = 132) and high-risk (n = 295) patients were 96.7% and 93.4%. For 70-gene signature low-risk-AOL high-risk patients (n = 124), of whom 76% (n = 94) had not received ACT, 5-year DRFI was 98.4%. In the AOL high-risk group, 32% (94/295) less patients would be eligible to receive ACT if the 70-gene signature was used. In this prospective community-based observational study, the 5-year DRFI probabilities confirmed the additional prognostic value of the 70-gene signature to clinicopathological risk estimations such as AOL. Omission of adjuvant chemotherapy as judged appropriate by doctors and patients and instigated by a low-risk 70-gene signature result, appeared not to compromise outcome.

Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
Mariantonietta Colozza, Evandro de Azambuja, +2 authors, Martine J Piccart.
Oncologist, 2006 Feb 16; 11(2). PMID: 16476832
Review.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.
Valesca P Retèl, Manuela A Joore, +3 authors, Wim H van Harten.
Eur J Cancer, 2010 Apr 03; 46(8). PMID: 20359886
Converting a breast cancer microarray signature into a high-throughput diagnostic test.
Annuska M Glas, Arno Floore, +9 authors, Laura J Van't Veer.
BMC Genomics, 2006 Nov 01; 7. PMID: 17074082    Free PMC article.
Highly Cited.
Commercialized multigene predictors of clinical outcome for breast cancer.
Jeffrey S Ross, Christos Hatzis, +2 authors, Gabriel N Hortobágyi.
Oncologist, 2008 Jun 03; 13(5). PMID: 18515733
Review.
Impact of mammographic screening on the detection of good and poor prognosis breast cancers.
Laura J Esserman, Yiwey Shieh, +8 authors, Laura J van 't Veer.
Breast Cancer Res Treat, 2011 Sep 06; 130(3). PMID: 21892702    Free PMC article.
Review.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.
S Mook, M K Schmidt, +7 authors, L J van 't Veer.
Ann Oncol, 2009 Oct 15; 21(4). PMID: 19825882
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Jolien M Bueno-de-Mesquita, Wim H van Harten, +19 authors, Sabine C Linn.
Lancet Oncol, 2007 Nov 29; 8(12). PMID: 18042430
Quality of Life Differences between Younger and Older Breast Cancer Patients.
Byeong-Woo Park, Suyun Lee, +2 authors, Sook Yeon Hwang.
J Breast Cancer, 2011 Aug 19; 14(2). PMID: 21847405    Free PMC article.
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
Validation of 70-gene prognosis signature in node-negative breast cancer.
J M Bueno-de-Mesquita, S C Linn, +16 authors, M J van de Vijver.
Breast Cancer Res Treat, 2008 Sep 27; 117(3). PMID: 18819002
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Clifford A Hudis, William E Barlow, +8 authors, Jo Anne Zujewski.
J Clin Oncol, 2007 May 22; 25(15). PMID: 17513820
Highly Cited.
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), M Clarke, +9 authors, W C Wood.
Lancet, 2008 Jan 08; 371(9606). PMID: 18177773
Review.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.
Jan Bogaerts, Fatima Cardoso, +12 authors, TRANSBIG consortium.
Nat Clin Pract Oncol, 2006 Oct 05; 3(10). PMID: 17019432
Review.
Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?
Philippe L Bedard, Fatima Cardoso.
Nat Rev Clin Oncol, 2011 Mar 03; 8(5). PMID: 21364525
Review.
Breast cancer: Genetic signature trumps clinicopathological features.
Lisa Hutchinson.
Nat Rev Clin Oncol, 2013 Feb 20; 10(4). PMID: 23419960
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
A Goldhirsch, E P Winer, +5 authors, Panel members.
Ann Oncol, 2013 Aug 07; 24(9). PMID: 23917950    Free PMC article.
Highly Cited.
Molecular profiling for breast cancer: a comprehensive review.
Muaiad Kittaneh, Alberto J Montero, Stefan Glück.
Biomark Cancer, 2013 Nov 20; 5. PMID: 24250234    Free PMC article.
Review.
Long-term impact of the 70-gene signature on breast cancer outcome.
C A Drukker, H van Tinteren, +4 authors, L J Van't Veer.
Breast Cancer Res Treat, 2014 Jan 22; 143(3). PMID: 24445566    Free PMC article.
Mammographic screening detects low-risk tumor biology breast cancers.
C A Drukker, M K Schmidt, +8 authors, L J Van't Veer.
Breast Cancer Res Treat, 2014 Jan 29; 144(1). PMID: 24469641    Free PMC article.
Molecular tests as prognostic factors in breast cancer.
Marc J van de Vijver.
Virchows Arch, 2014 Feb 04; 464(3). PMID: 24487789
Review.
Milestone approval lifts Illumina's NGS from research into clinic.
Cormac Sheridan.
Nat Biotechnol, 2014 Feb 11; 32(2). PMID: 24509734
Genomic profiling in luminal breast cancer.
Oleg Gluz, Daniel Hofmann, +3 authors, Nadia Harbeck.
Breast Care (Basel), 2014 Feb 20; 8(6). PMID: 24550749    Free PMC article.
Review.
Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.
J Wason, A Marshall, +2 authors, N Stallard.
Br J Cancer, 2014 Mar 29; 110(8). PMID: 24667651    Free PMC article.
The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients.
S Krenn-Pilko, U Langsenlehner, +5 authors, T Langsenlehner.
Br J Cancer, 2014 Mar 29; 110(10). PMID: 24675383    Free PMC article.
Highly Cited.
Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms.
C A Drukker, M V Nijenhuis, +10 authors, S C Linn.
Breast Cancer Res Treat, 2014 Apr 25; 145(3). PMID: 24760482    Free PMC article.
The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer.
R Exner, Z Bago-Horvath, +9 authors, P Dubsky.
Br J Cancer, 2014 Jul 09; 111(5). PMID: 25003667    Free PMC article.
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.
Laura Zanotti, Alberto Bottini, +2 authors, Maria Rosa Cappelletti.
Tumour Biol, 2014 Jul 23; 35(9). PMID: 25048969
Review.
Biological subtypes of breast cancer: Prognostic and therapeutic implications.
Ozlem Yersal, Sabri Barutca.
World J Clin Oncol, 2014 Aug 13; 5(3). PMID: 25114856    Free PMC article.
Highly Cited. Review.
Hurdles on the road to personalized medicine.
Thomas Tursz, Rene Bernards.
Mol Oncol, 2014 Sep 18; 9(5). PMID: 25226812    Free PMC article.
Review.
Breast cancer in young women: special considerations in multidisciplinary care.
Chantal Reyna, Marie Catherine Lee.
J Multidiscip Healthc, 2014 Oct 11; 7. PMID: 25300196    Free PMC article.
Review.
Update on adjuvant chemotherapy for early breast cancer.
Murtuza M Rampurwala, Gabrielle B Rocque, Mark E Burkard.
Breast Cancer (Auckl), 2014 Oct 23; 8. PMID: 25336961    Free PMC article.
Review.
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence.
Amalia M Issa, Vivek S Chaudhari, Gary E Marchant.
Expert Rev Mol Diagn, 2014 Dec 06; 15(2). PMID: 25479414    Free PMC article.
Review.
Multigene prognostic tests in breast cancer: past, present, future.
Balázs Győrffy, Christos Hatzis, +3 authors, Lajos Pusztai.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25848861    Free PMC article.
Highly Cited. Review.
Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?
Wilbert Zwart, Huub Terra, Sabine C Linn, Sanne B Schagen.
Nat Rev Clin Oncol, 2015 Jul 22; 12(10). PMID: 26196252
Review.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study.
A Kuijer, A C M van Bommel, +7 authors, Th van Dalen.
Genet Med, 2015 Nov 20; 18(7). PMID: 26583684
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives.
Meagan B Myers.
Pharmgenomics Pers Med, 2016 Feb 10; 9. PMID: 26858530    Free PMC article.
Review.
Equivalence of MammaPrint array types in clinical trials and diagnostics.
Inès Beumer, Anke Witteveen, +11 authors, Annuska Glas.
Breast Cancer Res Treat, 2016 Mar 24; 156(2). PMID: 27002507    Free PMC article.
Big data and computational biology strategy for personalized prognosis.
Ghim Siong Ow, Zhiqun Tang, Vladimir A Kuznetsov.
Oncotarget, 2016 Oct 26; 7(26). PMID: 27229533    Free PMC article.
Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.
Renata A Canevari, Fabio A Marchi, +5 authors, Eduardo M Reis.
Tumour Biol, 2016 Aug 04; 37(10). PMID: 27485113
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.
Jan C Brase, Ralf Kronenwett, +2 authors, Marcus Schmidt.
Microarrays (Basel), 2013 Jan 01; 2(3). PMID: 27605191    Free PMC article.
Review.
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Front Oncol, 2016 Nov 30; 6. PMID: 27896218    Free PMC article.
Review.
A breast cancer gene signature for indolent disease.
Leonie J M J Delahaye, Caroline A Drukker, +8 authors, Annuska M Glas.
Breast Cancer Res Treat, 2017 Apr 30; 164(2). PMID: 28451965    Free PMC article.
Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer.
Hideya Takeuchi, Hirohumi Kawanaka, +3 authors, Tokujiro Yano.
PLoS One, 2017 May 11; 12(5). PMID: 28489884    Free PMC article.
Clinical utility of gene-expression signatures in early stage breast cancer.
Maryann Kwa, Andreas Makris, Francisco J Esteva.
Nat Rev Clin Oncol, 2017 Jun 01; 14(10). PMID: 28561071
Highly Cited. Review.
Internet tools to enhance breast cancer care.
Shlomit Strulov Shachar, Hyman B Muss.
NPJ Breast Cancer, 2016 Apr 27; 2. PMID: 28721377    Free PMC article.
MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.
Andreas Bösl, Andreas Spitzmüller, +3 authors, Felix Offner.
PLoS One, 2017 Aug 30; 12(8). PMID: 28850621    Free PMC article.
Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
Michaela Tsai, Shelly Lo, +11 authors, Hatem Soliman.
JAMA Oncol, 2017 Oct 28; 4(1). PMID: 29075751    Free PMC article.
Clinical utility of multigene profiling assays in early-stage breast cancer.
M C Chang, L H Souter, +6 authors, Molecular Oncology Advisory Committee.
Curr Oncol, 2017 Nov 02; 24(5). PMID: 29089811    Free PMC article.
Molecular Subtypes and Local-Regional Control of Breast Cancer.
Simona Maria Fragomeni, Andrew Sciallis, Jacqueline S Jeruss.
Surg Oncol Clin N Am, 2017 Nov 15; 27(1). PMID: 29132568    Free PMC article.
Review.
The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.
Ling Xin, Yin-Hua Liu, Tracey A Martin, Wen G Jiang.
World J Oncol, 2017 Nov 18; 8(2). PMID: 29147432    Free PMC article.
Review.
Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.
Oluwadamilola M Fayanju, Ko Un Park, Anthony Lucci.
Ann Surg Oncol, 2017 Nov 22; 25(2). PMID: 29159748    Free PMC article.
Review.
The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer.
Hideya Takeuchi, Miyuki Abe, +6 authors, Kenji Sugio.
PLoS One, 2017 Dec 08; 12(12). PMID: 29216259    Free PMC article.
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
R Colomer, I Aranda-López, +7 authors, J Palacios-Calvo.
Clin Transl Oncol, 2017 Dec 24; 20(7). PMID: 29273958    Free PMC article.
Review.
Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis.
Vineet K Dhiman, Michael J Bolt, Kevin P White.
Nat Rev Genet, 2017 Dec 28; 19(3). PMID: 29279606
Review.
Editorial: How Reproductive History Influences Our Breast Cancer Risk.
Robin L Anderson, Wendy V Ingman, Kara L Britt.
Front Oncol, 2018 Jan 30; 7. PMID: 29376022    Free PMC article.
Prognostic gene expression assays in breast cancer: are two better than one?
Joseph A Sparano.
NPJ Breast Cancer, 2018 May 31; 4. PMID: 29845110    Free PMC article.
An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers.
André Filipe Vieira, Fernando Schmitt.
Front Med (Lausanne), 2018 Sep 21; 5. PMID: 30234119    Free PMC article.
Review.
Panoptic View of Prognostic Models for Personalized Breast Cancer Management.
Geetanjali Saini, Karuna Mittal, +3 authors, Ritu Aneja.
Cancers (Basel), 2019 Sep 11; 11(9). PMID: 31500225    Free PMC article.
Review.
Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer.
Tanja Ovcaricek, Iztok Takac, Erika Matos.
Radiol Oncol, 2019 Sep 26; 53(3). PMID: 31553709    Free PMC article.
Review.
Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.
Laurence Slembrouck, Lauren Darrigues, +31 authors, Giuseppe Floris.
Transl Oncol, 2019 Sep 13; 12(12). PMID: 31513983    Free PMC article.
Nuclear SIPA1 activates integrin β1 promoter and promotes invasion of breast cancer cells.
Y Zhang, Y Gong, +10 authors, L Su.
Oncogene, 2014 Apr 08; 34(11). PMID: 24704834
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.
Hatem Soliman, Varsha Shah, +11 authors, William Audeh.
BMC Cancer, 2020 Feb 02; 20(1). PMID: 32005181    Free PMC article.
Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage.
Jieun Koh, Min Jung Kim.
Korean J Radiol, 2019 Jan 11; 20(1). PMID: 30627023    Free PMC article.
Elevated red cell distribution width to platelet count ratio predicts poor prognosis in patients with breast cancer.
Hideya Takeuchi, Miyuki Abe, +4 authors, Kenji Sugio.
Sci Rep, 2019 Mar 01; 9(1). PMID: 30816333    Free PMC article.
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A Matikas, T Foukakis, S Swain, J Bergh.
Ann Oncol, 2019 May 28; 30(7). PMID: 31131397    Free PMC article.
Review.
Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test.
Lorenza Mittempergher, Leonie Jmj Delahaye, +7 authors, Annuska M Glas. Electronic address: Annuska.Glas@agendia.com.
Transl Oncol, 2020 Mar 26; 13(4). PMID: 32208353    Free PMC article.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
Genomic Signatures in Luminal Breast Cancer.
Julian Puppe, Tabea Seifert, +3 authors, Wolfram Malter.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982645    Free PMC article.
Review.
CD44 is prognostic for overall survival in the NCI randomized trial on breast conservation with 25 year follow-up.
T Dan, S M Hewitt, +10 authors, N L Simone.
Breast Cancer Res Treat, 2013 Nov 28; 143(1). PMID: 24276281    Free PMC article.
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
R Wuerstlein, R Kates, +14 authors, WSG-PRIMe investigators in Germany, Austria, Switzerland.
Breast Cancer Res Treat, 2019 Feb 24; 175(2). PMID: 30796651    Free PMC article.
A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort.
P Dubsky, L Van't Veer, +13 authors, M Filipits.
ESMO Open, 2021 Jan 06; 6(1). PMID: 33399073    Free PMC article.
Long non-coding RNA LSINCT5 inactivates Wnt/β-catenin pathway to regulate MCF-7 cell proliferation and motility through targeting the miR-30a.
Guizhi Zhang, Wenbo Song.
Ann Transl Med, 2021 Jan 26; 8(24). PMID: 33490147    Free PMC article.
Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Maroun Bou Zerdan, Maryam Ibrahim, +2 authors, Hazem I Assi.
Front Oncol, 2021 Mar 06; 10. PMID: 33665165    Free PMC article.
Review.
Prognostic Cancer Gene Expression Signatures: Current Status and Challenges.
Yuquan Qian, Jimmy Daza, +4 authors, Andreas Teufel.
Cells, 2021 Apr 04; 10(3). PMID: 33804045    Free PMC article.
Review.